Pinnacle Medicines raised $89 million in a Series B to advance its oral peptide programs, pushing total capital raised to $134 million. The round was co-led by LAV and Foresite Capital, with additional participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors including Orbimed. The financing underscores investor appetite for oral delivery formats that can extend the clinical reach of peptide therapeutics beyond parenteral administration. As a young company in this space, Pinnacle is positioned to use the cash to develop candidates through preclinical and into future clinical milestones, aligning with the broader market focus on increasingly differentiated delivery platforms. For biotech professionals, the round is also a signal that peptide-based mechanisms remain attractive when coupled with delivery innovations that address stability and bioavailability constraints.